SCHEMBL25301075

SCHEMBL25301075

COc1cccc(Cn2ncc3c(N)cccc32)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 3/20 0.54
▸ MEN1 O00255 2/20 0.54
▸ ADORA2A P29274 1/20 0.53
▸ ADORA1 P30542 1/20 0.53
▸ PKM P14618 4/20 0.52
▸ ALDH1A1 P00352 3/20 0.48
▸ KDM4E B2RXH2 2/20 0.48
▸ POLB P06746 1/20 0.48
▸ MAPT P10636 1/20 0.48
▸ HPGD P15428 1/20 0.48
▸ MAPK1 P28482 1/20 0.48
▸ ATM Q13315 1/20 0.48
▸ SMN1; SMN2 Q16637 1/20 0.48
▸ L3MBTL1 Q9Y468 1/20 0.48
▸ AURKA O14965 1/20 0.46
▸ GRK2 P25098 1/20 0.46
▸ ROCK1 Q13464 1/20 0.46
▸ RPS6KA1 Q15418 1/20 0.46
▸ CMA1 P23946 1/20 0.46
▸ ROCK2 O75116 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25248984 0.89 PKM (0.47) KMT2AMEN1ADORA2AADORA1PKM
SCHEMBL3289718 0.87 CNR1 (0.50) PKMALDH1A1MAPTHPGDSMN1; SMN2
SCHEMBL9941816 0.84 MAOB (0.48) ALDH1A1KDM4EHPGDMAPK1SMN1; SMN2
SCHEMBL1801928 0.81 MEN1 (0.59) KMT2AMEN1ADORA2AADORA1PKM
SCHEMBL9941640 0.81 ADORA2A (0.57) ADORA2AADORA1
SCHEMBL30491679 0.81 PKM (0.48) KMT2AMEN1ADORA2AADORA1PKM
SCHEMBL25252708 0.81 PKM (0.48) KMT2AMEN1ADORA2AADORA1PKM
SCHEMBL1172524 0.81 RECQL (0.58) ADORA2AADORA1PKMALDH1A1MAPT
SCHEMBL3379521 0.79 EGFR (0.57) KMT2AMEN1ADORA2AADORA1PKM
SCHEMBL9941849 0.77 GRIN1 (0.50) ALDH1A1KDM4EPOLBL3MBTL1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250059172-A1 INDAZOLE COMPOUND AND PHARMACEUTICAL NIPPON SHINYAKU CO., LTD. (JP) 2025-02-20 — — US disclosed
EP-4458810-A1 INDAZOLE COMPOUND AND PHARMACEUTICAL Nippon Shinyaku Co., Ltd. (JP) 2024-11-06 — — EP disclosed
CN-118748993-A Indazole compounds and medicaments 日本新药株式会社 2024-10-08 — — CN disclosed
WO-2023127883-A1 INDAZOLE COMPOUND AND PHARMACEUTICAL 日本新薬株式会社 2023-07-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250059172-A1 INDAZOLE COMPOUND AND PHARMACEUTICAL MC5R, CYP3A5, PTGIS KMT2A 4348/4885MEN1 2451/4885ADORA2A 1597/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback